| Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? F Caso, L Costa, P Ruscitti, L Navarini, A Del Puente, R Giacomelli, ... Autoimmunity reviews 19 (5), 102524, 2020 | 313 | 2020 |
| Overlap connective tissue disease syndromes L Iaccarino, M Gatto, S Bettio, F Caso, M Rampudda, M Zen, A Ghirardello, ... Autoimmunity Reviews 12 (3), 363-373, 2013 | 235 | 2013 |
| Blau syndrome, clinical and genetic aspects P Sfriso, F Caso, S Tognon, P Galozzi, A Gava, L Punzi Autoimmunity reviews 12 (1), 44-51, 2012 | 151 | 2012 |
| Anakinra treatment in drug-resistant Behcet’s disease: a case series L Cantarini, A Vitale, P Scalini, CA Dinarello, D Rigante, R Franceschini, ... Clinical Rheumatology 34, 1293-1301, 2015 | 144 | 2015 |
| Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease F Caso, P Galozzi, L Costa, P Sfriso, L Cantarini, L Punzi RMD open 1 (1), e000097, 2015 | 129 | 2015 |
| Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis R Giacomelli, A Afeltra, A Alunno, E Bartoloni-Bocci, O Berardicurti, ... Autoimmunity reviews 18 (1), 93-106, 2019 | 126 | 2019 |
| Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues F Caso, D Rigante, A Vitale, OM Lucherini, L Costa, M Atteno, ... International Journal of Rheumatology 2013 (1), 513782, 2013 | 120 | 2013 |
| Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients L Costa, F Caso, M Atteno, A Del Puente, MA Darda, P Caso, A Ortolan, ... Clinical rheumatology 33, 833-839, 2014 | 119 | 2014 |
| Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study L Costa, F Caso, L D’Elia, M Atteno, R Peluso, A Del Puente, P Strazzullo, ... Clinical rheumatology 31, 711-715, 2012 | 117 | 2012 |
| Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients P Sfriso, R Priori, G Valesini, S Rossi, CM Montecucco, A D’Ascanio, ... Clinical rheumatology 35, 1683-1689, 2016 | 109 | 2016 |
| Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease L Cantarini, G Lopalco, F Caso, L Costa, F Iannone, G Lapadula, ... Autoimmunity Reviews 14 (1), 1-9, 2015 | 106 | 2015 |
| Diagnosis and classification of relapsing polychondritis L Cantarini, A Vitale, MG Brizi, F Caso, B Frediani, L Punzi, M Galeazzi, ... Journal of Autoimmunity 48, 53-59, 2014 | 105 | 2014 |
| Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease … M Atteno, R Peluso, L Costa, S Padula, S Iervolino, F Caso, A Sanduzzi, ... Clinical rheumatology 29, 399-403, 2010 | 105 | 2010 |
| Biological treatments: new weapons in the management of monogenic autoinflammatory disorders A Vitale, D Rigante, OM Lucherini, F Caso, I Muscari, F Magnotti, MG Brizi, ... Mediators of Inflammation 2013 (1), 939847, 2013 | 98 | 2013 |
| Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis F Caso, L Costa, D Rigante, A Vitale, R Cimaz, OM Lucherini, P Sfriso, ... Autoimmunity Reviews 13 (12), 1220-1229, 2014 | 96 | 2014 |
| The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up L Cantarini, D Rigante, G Merlini, A Vitale, F Caso, OM Lucherini, P Sfriso, ... Seminars in Arthritis and Rheumatism 43 (6), 818-823, 2014 | 96 | 2014 |
| Biological Treatments in Behçet’s Disease: Beyond Anti‐TNF Therapy F Caso, L Costa, D Rigante, OM Lucherini, P Caso, V Bascherini, ... Mediators of inflammation 2014 (1), 107421, 2014 | 93 | 2014 |
| Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease: a case series A Vitale, D Rigante, F Caso, MG Brizi, M Galeazzi, L Costa, ... Dermatology 228 (3), 211-214, 2014 | 91 | 2014 |
| Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study L Costa, F Caso, R Ramonda, A Del Puente, L Cantarini, MA Darda, ... Immunologic research 61, 147-153, 2015 | 87 | 2015 |
| Psoriatic arthritis and psoriasis: differential diagnosis M Napolitano, F Caso, R Scarpa, M Megna, A Patrì, N Balato, L Costa Clinical rheumatology 35, 1893-1901, 2016 | 83 | 2016 |
Luca CantariniUniversity of Siena在 unisi.it 的电子邮件经过验证
